Hovione Announces a Co-Promotion & Collaboration Agreement
Hovione recently announced a co-promotion and collaboration agreement with Ligand to provide Hovione’s customers efficient access to Captisol technology.
Captisol, a chemically modified cyclodextrin, is proven to improve the solubility and stability of drugs and is currently used in six marketed products. Hovione offers innovative particle engineering technologies to improve the solubility of modern drugs. The agreement allows Hovione to use Captisol technology in its solubilization programs, which include amorphous solid dispersions, crystal design and size reduction, and control of particle size. By adding this new technology, it increases the likelihood of solving the molecule’s bioavailability challenges.
“Hovione is delighted to announce the ability to provide access to Captisol.There is no single solution to improving bioavailability and for a customer to access diverse options with a single supplier provides for greater probability of success and speedier outcomes,” said Dr. Colin Minchom, Hovione’s Vice President of Particle Design.
“Hovione has manufactured Captisol for more than a decade, and we are very pleased to expand our partnership to help customers succeed. Providing for greater access to Captisol should efficiently enable the successful development of more poorly soluble molecules and further increase our Captisol partnership portfolio,” said Mr. Mathew W. Foehr, Ligand’s Executive Vice President and Chief Operating Officer.
Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists at the University of Kansas’ Higuchi Biosciences Center for specific use in drug development and formulation. This unique technology has enabled six FDA-approved products, including Onyx Pharmaceuticals’ Kyprolis, Baxter International’s Nexterone, and Pfizer’s Vfend IV. There are currently more than 30 Captisol-enabled products in development, including Lundbeck’s carbamazepine IV, The Medicines Company’s MDCO-157, and Rib-X’s delafloxacin IV program.
Hovione is a global company with over 50 years’ experience in API and Drug Product Intermediate development and compliant manufacture. With four FDA-inspected sites in the US, China, Ireland, and Portugal, the company focuses on the most demanding customers in the most regulated markets. Hovione offers integrated API, particle design, formulation development, and GMP manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.
For more information about Hovione, please visit www.hovione.com or contact Marketing & Communication, Isabel Pina, + 351 21 982 9362, e-mail: ipina@hovione.com. Follow Hovione on Twitter @HovioneGroup and LinkedIn.
Total Page Views: 1180
